Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 532 participants.
Also called NCT05295628
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Not applicable
- Enrolled
- 532 participants
- Registry
-
NCT05295628
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05295628. Randomized; double masking; primary purpose prevention. Start 2023-10-17 (actual); primary completion 2025-05-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
- Condition
- Aortic Valve Stenosis
- Condition
- Aortic Valve Disease
- Condition
- Aortic Valve Insufficiency
- Condition
- Aortic Valve Replacement
- Intervention (Device)
- EMBLOK™ Embolic Protection System ("EMBLOK EPS")
- Intervention (Device)
- SENTINEL™ Cerebral Protection System
- Lead sponsor
- Emblok, Inc.
- Collaborator
- Yale Cardiovascular Research Group
Record details
- Record id
cardio:ct-nct05295628- Content hash
c2e49a8b351ac8d2b1c97cd5b8b196bba2b2d524d439a85a8105b44f8390e01e